🏢 What kind of company is AC Immune?

AC Immune (ACIU) is a clinical-stage biotech company headquartered in Switzerland. It has developed both active immunotherapies and small-molecule therapies that target misfolded proteins — such as tau, amyloid-beta, and alpha-synuclein — identified as drivers of neurodegenerative diseases.

It develops therapeutic and diagnostic candidates centered on neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The company operates two proprietary platforms — the SupraAntigen vaccine platform and the Morphomer small-molecule platform — and runs a diversified pipeline spanning Phase 2 and Phase 1b clinical stages.

💰 How does AC Immune make money?

As a clinical-stage biotech, revenue is heavily dependent on milestone and licensing payments from collaboration partners as well as research grants. The revenue scale tends to fluctuate significantly from quarter to quarter, depending on the timing of milestone recognition tied to pipeline progress. At this stage, the company has no proprietary product sales, so operating losses are dictated by the scale of R&D investment. Recently, the company has been focused on slowing its cash burn through workforce efficiency and securing visibility on its operating runway.

📐 AC Immune market cap and company scale

Its market cap stands at approximately $273.8M, and the company employs approximately 122 people people.

AC Immune is a small clinical-stage biotech in the global neurodegenerative immunotherapy space, where corporate value is weighted more toward pipeline potential and big-pharma collaborations than proprietary revenue. It is grouped alongside other small biotechs in the neurodegeneration space such as ALEC and PMN. Given its clinical-stage nature, capital is concentrated on securing cash and reinvesting in R&D rather than on dividends.

📈 AC Immune outlook and stock price trends

Phase 2 clinical data readouts for its active immunotherapy candidates in Alzheimer's and Parkinson's, along with development progress at partners including Johnson & Johnson, are the medium- to long-term key drivers. A multi-target pipeline aimed at tau, amyloid-beta, and alpha-synuclein, along with a small-molecule program targeting the inflammasome complex, could serve as a value-expansion lever. In the short term, interim data readouts from individual clinical trials, the achievement of collaboration milestones, the cash burn rate, and the need for additional financing are factors that can significantly amplify stock-price volatility.

• Progress of Phase 2 clinical data in Alzheimer's and Parkinson's
• Big-pharma collaboration milestones and new partnerships
• Value expansion of the small-molecule and diagnostic platforms

⚔️ AC Immune core strengths and risks

A diversified neurodegeneration pipeline and big-pharma collaborations are strengths, while clinical failure risk and cash burn pressure are the core risks.

🔄 AC Immune competitors and related (beneficiary) stocks

Direct competitors developing therapeutics for neurodegenerative diseases group together with ALEC, which focuses on brain-penetrant antibodies, PMN, with antibodies targeting misfolded proteins, and PRTA, which targets protein aggregation. Related names that tend to move on the same thematic drivers include large-cap pharma BIIB, which leads in commercialized Alzheimer's treatments, and another neurodegeneration-focused biotech DNLI.

✅ AC Immune investor checkpoints

Key checkpoints to monitor when investing in AC Immune. Given its clinical-stage nature, pipeline data outcomes and cash position are the short-term core variables, while big-pharma collaboration progress and the need for additional financing also warrant close observation.

Because late-stage clinical failure rates are high in the neurodegeneration space, individual trial data readouts can generate significant stock-price volatility. With no proprietary product revenue, cash burn and the possibility of share dilution through additional financing remain core risks, and shifts in the development priorities of collaboration partners are another source of volatility.

AC Immune is a clinical-stage biotech with a diversified pipeline in neurodegenerative immunotherapy and big-pharma collaborations. With clinical data readouts and cash runway visibility as the key variables to monitor, dollar-cost averaging and a long-term perspective are recommended given the elevated volatility.